Key Takeaways
- Resilient quarter, cautious tone: International Services revenue grew +0.6% QoQ in USD but declined 0.9% in constant currency, as tariff-driven uncertainty in Retail and Manufacturing plus budget pressures at two large clients offset a major TMT deal ramp.
- Large deal engine is the stabilizer: A $73 mn TMT deal announced in April is 70-80% ramped and helped absorb headwinds; three more large deals were signed in Q1 across BFSI and TMT.
- AI is becoming a disclosed growth vector: AI pipeline reached $46 mn in Q1, and management expects AI-enabled services to contribute 20% of revenue over three years, supported by the AgentBridge launch and new AI co-innovation lab wins.
- Margins held flat but wage hikes loom: EBITDA inched up 10 bps to 16.6%, but annual compensation revisions begin in Q2 and will pressure margins in the near term.
- What to watch next quarter: Whether the largest BFSI and Tech clients stabilize, the pace of the TMT deal's full ramp, and any resolution on the Microsoft direct-engagement risk in domestic business.
Demand Environment
- What hurt Q1: Tariff announcements triggered softness in Retail, Manufacturing and Distribution that has persisted for 2-3 quarters and is not yet fully behind the company. Two large clients, one in BFSI and one in High-Tech, are under budget pressure and cutting discretionary spend.
- What held up: Healthcare, Life Sciences and BFSI together now exceed 30% of total revenue, up from 13% three years ago, driven by Data and AI-led deal wins and new logo additions. The large TMT deal ramp provided a meaningful offset.
- The uncertainty is still evolving: Tariffs are being signed off by countries and sectors almost weekly, and management describes the situation as an evolving balance between tailwinds in Healthcare and Data/AI and headwinds in the largest Tech client, largest BFSI client, and Retail Manufacturing.
Samir Dhir: "I think our tailwinds continue to the Health Care vertical, tailwinds continue to Data and AI side. Our headwinds continue to be our largest Tech client and largest BFSI client and Retail Manufacturing. I think we are just trying to balance out the positives and the negatives. And it's an evolving situation candidly."
Deal Wins & Pipeline
Three large deals closed in Q1, spanning core modernization, platform consolidation, and partnership expansion. Large deals remain roughly 45% of the pipeline.
| Deal | Details |
|---|---|
| BFSI lending platform | Multiyear contract to modernize a core lending platform and transform cloud/infra for a leading BFSI client. |
| Global TMT leader | Renewed and expanded partnership with a software and cloud services provider, with additional budgets committed. |
| BFSI data platform | Consolidation and modernization of data platform support and core application development for a BFSI client. |
| TMT mega deal ($73 mn) | Announced in April, now 70-80% ramped; remaining staffing to complete by October. The ramp benefited TMT this quarter and will continue into Q2. |
| AI co-innovation lab | Multi-year engagement with a global agriculture leader to build an AI lab for custom copilots aimed at the trading desk. |
| Answer engine optimization | Large Europe-based client transforming digital acquisition strategy from search engine optimization to answer engine optimization. |
- New customer additions: 7 new enterprise-grade logos opened in Q1 through Microsoft, AWS and other ecosystem partnerships; these will scale gradually through Q2-Q4.
- Client bucket movement: Clients with >$5M run rate increased to 13 from 11; some clients moved up while others saw project completions or run-rate reductions, with no client losses.
Vertical Performance
| Vertical | Trend | Commentary |
|---|---|---|
| Healthcare & Life Sciences | ▲ Strong | Growth driven by Pharma (new logos, disintermediating incumbents in Data and AI) and Health Tech (platform builds with modern engineering and AI). |
| BFSI | ▬ Mixed | Reasonably optimistic for the year, but the largest client (a large U.S. bank) has had budget shrinkage for two quarters with no line of sight on Q2-Q4 budgets yet. Backing out that single client, good momentum is expected. |
| TMT | ▲ Benefiting from ramp | The mega deal ramp drove TMT growth this quarter and will continue into Q2. The largest TMT client is flattish, awaiting a new budget rollout that has not yet concluded. |
| Retail & Manufacturing | ▼ Soft | Tough for 2-3 quarters since tariffs were announced; impact is not fully behind them and further impact remains unclear. |
| IT & ITES (Domestic) | ▼ Declined | Gross contribution fell 12.6% QoQ on sector softness, plus risk from a partner exploring a direct engagement model with customers. |
AI & GenAI
- Revenue ambition: AI-enabled services are expected to contribute 20% of Sonata's revenue over the next 3 years, with AI opportunities now spanning 100-plus clients and a pipeline of nearly $46 mn in Q1.
- AgentBridge launch: Sonata launched AgentBridge, positioning itself as one of the first mid-tier firms with enterprise-grade agentic AI workflows.
- AI wins in the quarter: A global agriculture leader signed a multi-year AI co-innovation lab for custom copilots; a large European client engaged Sonata to shift from search engine optimization to answer engine optimization.
- Internal AI adoption: Sonata GPT was rolled out for HR and support functions, with bots deployed for policy access, internal automation queries, and developer productivity tools.
- Research partnerships: Sonata became a thought leadership partner with the Wharton AI & Analytics Initiative for agentic AI research and governance, and formed a partnership with IISc in India for deep tech and AI innovation.
Samir Dhir: "We launched AgentBridge recently, making Sonata one of the first mid-tier firms with enterprise-grade agentic AI workflows."
Margins & Financials
| Metric | Q1 FY26 | Context |
|---|---|---|
| EBITDA margin | 16.6% | Up 10 bps QoQ from 16.5%. |
| International Services revenue (USD) | +0.6% QoQ | Constant currency degrowth of 0.9% QoQ and 2.4% YoY. |
| Domestic revenue | +18.6% QoQ, +23% YoY | Gross contribution declined 12.6% QoQ on IT/ITES softness. |
| Cash & equivalents | INR 600 crores | Down from INR 707 crores on Quant earnout payment and incremental loan repayment. |
| Net cash | Negative INR 62.5 crores | Additional $35 mn loan taken to pay Quant earnout. |
| DSO (Domestic) | 63 days | Up from 43 days in Q4 on seasonal billing timing; same period last year was 65 days. |
| On-site/Offshore mix | 47% / 53% | Shifted from 51% / 49% in Q4. |
| Headcount | 6,859 | Up from 6,810; attrition at 16%. |
- Wage hike timing: Junior and middle management increments effective August 1 (Q2); senior management from October 1. The margin impact is expected to be similar to past years.
- Margin improvement path: Management is working on utilization improvement and pyramid optimization, and expects the large deal ramp to shift the on-site/offshore mix favorably. However, margin improvement will materialize only once revenue growth stabilizes and market uncertainties resolve.
- Quant earnout: The original earnout was paid in full this quarter, funded partly by a new $35 mn loan. A new 3-year contract was signed with incremental performance obligations and a revised estimate rolled over; no reversals of provisions are expected.
- RBI issue resolved: The regulatory issue has been cleared, enabling movement of money between Sonata entities to fund growth investments.
People & Organization
- Sales leadership: Hired a Head of Retail and Manufacturing vertical in the U.S. and a Head of BFSI vertical in the U.S. during the quarter.
- Compensation: Annual compensation revisions for all team members globally begin in Q2.
- Dividend policy shift: The company declared a first interim dividend of INR 1.25 per share and expects to pay quarterly interim dividends going forward.
- Top client concentration: Revenue share from the top 10 clients decreased from 61% to 56%, a positive diversification signal.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year growth | Positive growth for the full year, based on order book momentum, despite Q1 YoY negative growth. | FY26 |
| TMT mega deal ramp | Nearly fully ramped up; remaining staffing in Aug-Oct. | By Q2 results (October) |
| Largest client recovery | The largest client with issues expected to return to growth. | "Maybe from Q2 timeframe"; update in Oct/Nov |
| AI revenue contribution | AI-enabled services to reach 20% of total revenue. | Over next 3 years |
| Healthcare + BFSI scale | Combined Healthcare, Life Sciences and BFSI revenue to reach $250 mn. | Over next 3 to 5 years |
| Wage hike impact | Margin impact from annual compensation revisions. | Q2 (junior/middle), Q3 (senior) |
Key Metrics
| Metric | Q1 FY26 |
|---|---|
| Consolidated revenue | ₹2,965.2 cr, +13.3% QoQ and +17.3% YoY |
| International Services revenue | $81.8 mn, +0.6% QoQ and -1.1% YoY; constant currency -0.9% QoQ and -2.4% YoY |
| International Services rupee revenue | ₹699.9 cr, -0.3% QoQ and +1.8% YoY |
| Domestic business revenue | ₹2,274.7 cr, +18.6% QoQ and +23% YoY |
| International Services EBITDA margin | 16.6%, +10 bps QoQ |
| Domestic business gross contribution | ₹68.5 cr, -12.6% QoQ and flat YoY |
| Consolidated PAT before exceptional items | ₹109.3 cr, +1.7% QoQ and +3.5% YoY |
| Consolidated EPS | ₹3.94 per share, +1.8% QoQ |
| International Services PAT | ₹70.7 cr, vs ₹62.3 cr in Q4 |
| Domestic business PAT | ₹38.6 cr, -14.6% QoQ and -4.6% YoY |
| Order book | $105 mn, book-to-bill ratio of 1.08x |
| Large deals won | 3 in Q1 |
| AI pipeline | $46 mn in Q1 |
| Clients with >$10 mn annual run rate | 7 |
| Clients with >$5 mn run rate | 13, vs 11 in Q4 |
| New customers added | 7 in Q1 |
| Top 10 clients revenue share | 56%, vs 61% in Q4 |
| Total headcount | 6,859, vs 6,810 in Q4 |
| LTM attrition | 16% |
| Utilization | 86.6%, marginal drop QoQ |
| On-site/offshore revenue mix | 47:53, vs 51:49 in Q4 |
| Cash and cash equivalents | ₹600 cr, vs ₹707 cr in Q4 |
| Net cash balance | Negative ₹62.5 cr |
| DSO (International business) | 62 days |
| DSO (Domestic business) | 63 days, vs 43 days in Q4 |
| Consolidated ROCE | 18.5% |
| Consolidated RONW | 24% |
| Interim dividend declared | ₹1.25 per share, quarterly interim dividends expected going forward |
| AI-trained workforce | 93.5% |
| Gender diversity | 31% |
| BFSI and Healthcare Life Sciences revenue share | Over 30% of total revenue, up from 13% three years ago |
| Large and strategic opportunities in pipeline | ~45% of pipeline |
| TMT revenue growth | +15% QoQ |
| Additional loan taken | $35 mn for Quant earnout payment |